Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegasys in CML with minimal residual disease
NCT01392170Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2011
- Primary completion
- Mar 2014
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label trial of interferon alfa in Chronic Myeloid Leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2011; status: terminated.
02
Drugs
interferon alfa
03
Conditions
Chronic Myeloid Leukemia (CML)
Beyond the preview
Go deeper on NCT01392170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01392170.